As of 2025-07-19, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -59.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 3,056.63 mil USD. SRPT's TTM EBITDA according to its financial statements is -51.77 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.8x - 13.1x | 11.8x |
| Forward P/E multiples | 11.9x - 31.9x | 16.2x |
| Fair Price | (9.48) - 83.39 | 14.81 |
| Upside | -167.4% - 492.5% | 5.2% |
| Date | EV/EBITDA |
| 2025-07-18 | -59.04 |
| 2025-07-17 | -82.43 |
| 2025-07-16 | -71.80 |
| 2025-07-15 | -71.29 |
| 2025-07-14 | -74.32 |
| 2025-07-11 | -71.17 |
| 2025-07-10 | -73.83 |
| 2025-07-09 | -74.73 |
| 2025-07-08 | -73.72 |
| 2025-07-07 | -68.66 |
| 2025-07-03 | -71.38 |
| 2025-07-02 | -71.25 |
| 2025-07-01 | -69.81 |
| 2025-06-30 | -68.00 |
| 2025-06-27 | -68.03 |
| 2025-06-26 | -68.39 |
| 2025-06-25 | -69.07 |
| 2025-06-24 | -73.57 |
| 2025-06-23 | -73.25 |
| 2025-06-20 | -76.83 |
| 2025-06-18 | -78.88 |
| 2025-06-17 | -81.22 |
| 2025-06-16 | -79.38 |
| 2025-06-13 | -124.54 |
| 2025-06-12 | -127.89 |
| 2025-06-11 | -129.37 |
| 2025-06-10 | -133.10 |
| 2025-06-09 | -135.00 |
| 2025-06-06 | -144.78 |
| 2025-06-05 | -133.52 |
| 2025-06-04 | -134.50 |
| 2025-06-03 | -132.51 |
| 2025-06-02 | -129.16 |
| 2025-05-30 | -128.75 |
| 2025-05-29 | -131.74 |
| 2025-05-28 | -127.65 |
| 2025-05-27 | -130.97 |
| 2025-05-23 | -129.64 |
| 2025-05-22 | -132.27 |
| 2025-05-21 | -136.01 |
| 2025-05-20 | -135.83 |
| 2025-05-19 | -129.76 |
| 2025-05-16 | -125.28 |
| 2025-05-15 | -121.84 |
| 2025-05-14 | -123.24 |
| 2025-05-13 | -124.60 |
| 2025-05-12 | -125.10 |
| 2025-05-09 | -124.81 |
| 2025-05-08 | -125.55 |
| 2025-05-07 | -126.14 |